Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 8.59%.

  • Arcutis Biotherapeutics' EBIT Margin rose 958800.0% to 8.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.03%, marking a year-over-year increase of 1191300.0%. This contributed to the annual value of 65.33% for FY2024, which is 3391600.0% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' EBIT Margin is 8.59%, which was up 958800.0% from 17.93% recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year EBIT Margin high stood at 8.59% for Q3 2025, and its period low was 14448.0% during Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median EBIT Margin value was 123.01% (recorded in 2023), while the average stood at 1671.81%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 143249900bps in 2023, then surged by 265400bps in 2025.
  • Arcutis Biotherapeutics' EBIT Margin (Quarter) stood at 2310.84% in 2022, then skyrocketed by 80bps to 452.23% in 2023, then surged by 98bps to 10.7% in 2024, then soared by 180bps to 8.59% in 2025.
  • Its EBIT Margin stands at 8.59% for Q3 2025, versus 17.93% for Q2 2025 and 37.25% for Q1 2025.